
views
SkinBioTherapeutics – interim numbers & warning of slight delay largely irrelevant, the clear potential remains - Buy
SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.
- By Tom Winnifrith & Steve Moore
- 2022-03-31 09:52:33